Myotubularin-related protein 7 activates peroxisome proliferator-activated receptor-gamma
Authors:
Open Access
- 10 June 2020
- journal article
- research article
- Published by Springer Nature in Oncogenesis
- Vol. 9 (6) , 1-14
Abstract
Peroxisome proliferator-activated receptor-gamma (PPARγ) is a transcription factor drugable by agonists approved for treatment of type 2 diabetes, but also inhibits carcinogenesis and cell proliferation in vivo. Activating mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) gene mitigate these beneficial effects by promoting a negative feedback-loop comprising extracellular signal-regulated kinase 1/2 (ERK1/2) and mitogen-activated kinase kinase 1/2 (MEK1/2)-dependent inactivation of PPARγ. To overcome this inhibitory mechanism, we searched for novel post-translational regulators of PPARγ. Phosphoinositide phosphatase Myotubularin-Related-Protein-7 (MTMR7) was identified as cytosolic interaction partner of PPARγ. Synthetic peptides were designed resembling the regulatory coiled-coil (CC) domain of MTMR7, and their activities studied in human cancer cell lines and C57BL6/J mice. MTMR7 formed a complex with PPARγ and increased its transcriptional activity by inhibiting ERK1/2-dependent phosphorylation of PPARγ. MTMR7-CC peptides mimicked PPARγ-activation in vitro and in vivo due to LXXLL motifs in the CC domain. Molecular dynamics simulations and docking predicted that peptides interact with the steroid receptor coactivator 1 (SRC1)-binding site of PPARγ. Thus, MTMR7 is a positive regulator of PPARγ, and its mimicry by synthetic peptides overcomes inhibitory mechanisms active in cancer cells possibly contributing to the failure of clinical studies targeting PPARγ.Keywords
Funding Information
- Deutsches Krebsforschungszentrum (Ca-158, Ca-158, Ca-158)
- Deutsche Krebshilfe (108287; 111086)
- JB, PW and TG received support from the “Translational Physician Scientist” (TraPS) program; LH, TS and VH were awarded MD fellowships (all from the Medical Faculty Mannheim).
- This study was supported by grants to RS from the Deutsches Krebsforschungszentrum (DKFZ, German Cancer Research Center) and the Israel Ministry of Science and Technology (MOST) (Ca158
- Klaus Tschira Stiftung
- Alexander von Humboldt-Stiftung
This publication has 66 references indexed in Scilit:
- Drugging the undruggable RAS: Mission Possible?Nature Reviews Drug Discovery, 2014
- Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancerInvestigational New Drugs, 2013
- Targeting the ERBB family in cancer: couples therapyNature Reviews Cancer, 2013
- Thiazolidinediones and PPARγ agonists: time for a reassessmentTrends in Endocrinology & Metabolism, 2012
- The role of peroxisome proliferator-activated receptors in carcinogenesis and chemopreventionNature Reviews Cancer, 2012
- Crosstalk between the canonical NF-κB and Notch signaling pathways inhibits Pparγ expression and promotes pancreatic cancer progression in miceJournal of Clinical Investigation, 2011
- Nuclear receptor transrepression pathways that regulate inflammation in macrophages and T cellsNature Reviews Immunology, 2010
- Colorectal Cancer Expression of Peroxisome Proliferator-Activated Receptor γ (PPARG, PPARgamma) Is Associated With Good PrognosisGastroenterology, 2009
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal CancerNew England Journal of Medicine, 2008
- Peroxisome-proliferator-activated receptors and cancers: complex storiesNature Reviews Cancer, 2004